Literature DB >> 16821064

[Cost predictors of depressive inpatient episodes in Germany. The health insurer's point of view].

K Stamm1, H J Salize, M Härter, S Brand, P Sitta, M Berger, W Gaebel, F Schneider.   

Abstract

BACKGROUND: Inpatient treatment is the most costly sector of treatment for depressive disorders in Germany. However, little is known about which patient and hospital characteristics contribute to costs of inpatient episodes. PATIENTS AND METHODS: To take part in this study, patients had to fullfill criteria for ICD-10 diagnosis of F31.3-F31.5, F32, F33, F34.1, F43.20, or F43.21. Episodes were recorded between September 9 2001 and March 3 2003 in ten hospitals in three German states. Inpatient records of 1,202 persons were analysed. Multiple regression analysis was performed to identify significant patient predictors of cost per inpatient episode, and the predictive function of hospital characteristics was analysed by applying hierarchical linear modeling.
RESULTS: Patient characteristics at admission could not explain a substantial part of the variance in episode costs. Better prediction was possible including variables from the whole treatment process. Also, conditions for admission and patient-related factors did not well explain cost differences between hospitals, but characteristics of the whole treatment were.
CONCLUSION: For predicting costs of inpatient depressive episodes, the complete course treatment has to be considered. As in the physiologic sector, therapeutic and diagnostic procedures have a great effect on cost prediction.

Entities:  

Mesh:

Year:  2007        PMID: 16821064     DOI: 10.1007/s00115-006-2115-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  6 in total

1.  [How significant is the comparison for length of stay in psychiatric hospitals based on diagnosis and age?].

Authors:  D Richter
Journal:  Gesundheitswesen       Date:  1999-05

2.  [Diagnosis related groups in psychiatry and psychotherapy--alternatives to DRGs].

Authors:  M Burgmer; G Heuft; H J Freyberger; N Roeder
Journal:  Nervenarzt       Date:  2003-03       Impact factor: 1.214

3.  [Alteration of the guidelines on pharmaceuticals of the National Committee of Physicians and Health Insurers with regard to atypical neuroleptics. Statement of the German Scoiety of Psychiatry, Psychotherapy and Neurology (DGPPN)].

Authors:  J Fritze; M Schmauss
Journal:  Nervenarzt       Date:  2003-01       Impact factor: 1.214

4.  Adherence to guidelines for treatment of depression in in-patients.

Authors:  Frank Schneider; Martin Härter; Silke Brand; Petra Sitta; Ralph Menke; Ursula Hammer-Filipiak; Ralf Kudling; Andrea Heindl; Kurt Herold; Ulrich Frommberger; Olivier Elmer; Günter Hetzel; Gabriele Witt; Manfred Wolfersdorf; Mathias Berger; Wolfgang Gaebel
Journal:  Br J Psychiatry       Date:  2005-11       Impact factor: 9.319

5.  [Data supporting quality circle management of inpatient depression treatment].

Authors:  S Brand; M Härter; P Sitta; D van Calker; R Menke; A Heindl; K Herold; R Kudling; C Luckhaus; U Rupprecht; Dirk Sanner; D Schmitz; E Schramm; M Berger; W Gaebel; F Schneider
Journal:  Nervenarzt       Date:  2005-07       Impact factor: 1.214

6.  [Cost of care for depressive disorders in primary and specialized care in Germany].

Authors:  Hans Joachim Salize; Klaus Stamm; Matthias Schubert; Frank Bergmann; Martin Härter; Mathias Berger; Wolfgang Gaebel; Frank Schneider
Journal:  Psychiatr Prax       Date:  2004-04
  6 in total
  3 in total

1.  [Integrated care for depressive disorders].

Authors:  M Paulzen; A Müller; T Akkus; F Bergmann; F Schneider
Journal:  Nervenarzt       Date:  2014-07       Impact factor: 1.214

Review 2.  [Innovative care models for treating depression].

Authors:  C Klesse; I Bermejo; M Härter
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

3.  Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants.

Authors:  Astrid Seidl; Marion Danner; Christoph J Wagner; Frank G Sandmann; Gaby Sroczynski; Heidi Stürzlinger; Johannes Zsifkovits; Anja Schwalm; Stefan K Lhachimi; Uwe Siebert; Andreas Gerber-Grote
Journal:  MDM Policy Pract       Date:  2018-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.